| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T643 |
0-178 |
Sentence |
denotes |
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group: |
| T644 |
179-234 |
Sentence |
denotes |
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip |
| T645 |
235-441 |
Sentence |
denotes |
No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020 |
